Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.

doi:10.1016/j.lungcan.2026.109305

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2026

Hayashi Hidetoshi, Cho Byoung Chul, Kim Yu Jung, Lee Se-Hoon, Danchaivijitr Pongwut, Alip Adlinda, Xiong Hailin, How Soon-Hin, Chang Gee-Chen, Yang James Chih-Hsin, Yamanaka Yuta, Nahit Şendur Mehmet Ali, Prabhash Kumar, Azuma Koichi, Akawung Alianu, Fennema Elizabeth, Tang Xiaodan, Shah Sujay, Sethi Seema, Lu Shun

Abstract excerpt

BACKGROUND: Approximately 60 % of lung cancer cases occur in Asia, indicating an epidemiological disparity and need for effective therapies. Amivantamab-lazertinib is approved for first-line EGFR-mutated advanced non-small cell lung cancer (NSCLC) in many countries. In the protocol-specified final overall survival (OS) analysis of MARIPOSA (NCT04487080), amivantamab-lazertinib showed a statistically significant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Indoles

Share to Pyrimidines

Share to Quinolines

Source

Open in PubMed

Identifiers

PMID: 41689889
DOI: 10.1016/j.lungcan.2026.109305

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.PMID 41689889Read ↗

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.Semantic proximity Read ↗

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinionSemantic proximity Read ↗

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.Semantic proximity Read ↗

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.Semantic proximity Read ↗

EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations.Semantic proximity Read ↗

Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.Semantic proximity Read ↗

MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSASemantic proximity Read ↗

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.Semantic proximity Read ↗

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.